Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zucapsaicin

Drug Profile

Zucapsaicin

Alternative Names: cis-Capsaicin; Civamide; Civamide 0.075% cream - Winston Pharmaceuticals; Civanex; Civanex Nasal Solution; Dolorac Nasal Solution; Neuroderm Patch; Zuacta

Latest Information Update: 14 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Winston Laboratories
  • Developer Sanofi; Winston Laboratories; Winston Pharmaceuticals
  • Class Catechols; Monounsaturated fatty acids; Polyunsaturated alkamides; Solanaceous alkaloids
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Phase II Keratoconjunctivitis sicca
  • No development reported Cluster headache; Crohn's disease; Migraine; Postherpetic neuralgia; Rhinitis

Most Recent Events

  • 14 Apr 2021 Winston Laboratories plans a phase III trial in Cluster headache (Prevention, In adults, In the elderly) (Intranasal) in November 2021 (NCT01341548)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 09 Jun 2015 No recent reports on development identified - Phase-II for Crohn's disease in USA (PO, capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top